Sun Pharma Reports 26% Year-on-Year Profit Increase in Q4 FY26
Sun Pharma Q4 Results: Cons profit rises 26% YoY to Rs 2,714 crore; board approves Rs 5/share dividend
Image: The Economic Times
Sun Pharmaceuticals announced a consolidated net profit of ₹2,714 crore (approximately $327 million USD) for the quarter ending March 2026, marking a 22% increase from the previous year. The company also declared a ₹5 per share dividend, pending approval at the upcoming Annual General Meeting.
- 01Revenue for Q4 FY26 reached ₹14,612 crore (approximately $1.8 billion USD), a 13% increase from ₹12,959 crore in the same quarter last year.
- 02The profit after tax (PAT) decreased 19% sequentially from ₹3,369 crore in Q3 FY26.
- 03Sequential revenue also fell by 6% from ₹15,520 crore reported in the previous quarter.
- 04The final dividend of ₹5 per equity share is subject to approval at the company's 34th Annual General Meeting.
- 05The results reflect a strong year-on-year performance despite sequential declines.
Advertisement
In-Article Ad
Sun Pharmaceuticals reported a consolidated net profit of ₹2,714 crore (approximately $327 million USD) for the quarter ending March 2026, reflecting a 22% increase from ₹2,150 crore in the same quarter last year. Revenue rose by 13% to ₹14,612 crore compared to ₹12,959 crore in the previous year. However, the profit after tax (PAT) saw a 19% decline sequentially from ₹3,369 crore in Q3 FY26, and revenue decreased by 6% from ₹15,520 crore in the previous quarter. The company’s board has proposed a final dividend of ₹5 per equity share, pending shareholder approval at the upcoming 34th Annual General Meeting.
Advertisement
In-Article Ad
The increase in profit and revenue suggests a positive outlook for Sun Pharma, which could benefit shareholders and investors in the pharmaceutical sector.
Advertisement
In-Article Ad
Reader Poll
Do you think the dividend payout reflects Sun Pharma's financial health?
Connecting to poll...
Read the original article
Visit the source for the complete story.